Lv1
40 积分 2021-10-16 加入
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
12小时前
已完结
Clinical development success rates for investigational drugs
1年前
已完结
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
1年前
已完结
Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations
1年前
已完结
Natural bioactive compounds and STAT3 against hepatocellular carcinoma: An update
1年前
已完结
Immunotherapy and Liver Transplantation
1年前
已完结
Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression
1年前
已完结
Current Perspectives of Immunotherapy for Hepatocellular Carcinoma
1年前
已关闭
Immunosuppression minimization is safe and associated with good long-term success in pediatric liver transplant recipients
1年前
已完结
Transplantation for Nonresectable Colorectal Liver Metastases: Long-Term Follow-Up of the First Prospective Pilot Study
1年前
已完结
皖公网安备34019202002308
